"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 3 | 6 |
| 1996 | 3 | 3 | 6 |
| 1997 | 3 | 7 | 10 |
| 1998 | 6 | 5 | 11 |
| 1999 | 2 | 6 | 8 |
| 2000 | 4 | 7 | 11 |
| 2001 | 3 | 12 | 15 |
| 2002 | 12 | 13 | 25 |
| 2003 | 12 | 11 | 23 |
| 2004 | 8 | 12 | 20 |
| 2005 | 15 | 7 | 22 |
| 2006 | 12 | 14 | 26 |
| 2007 | 12 | 11 | 23 |
| 2008 | 12 | 21 | 33 |
| 2009 | 20 | 19 | 39 |
| 2010 | 20 | 18 | 38 |
| 2011 | 20 | 23 | 43 |
| 2012 | 16 | 20 | 36 |
| 2013 | 18 | 17 | 35 |
| 2014 | 39 | 21 | 60 |
| 2015 | 31 | 22 | 53 |
| 2016 | 45 | 40 | 85 |
| 2017 | 77 | 46 | 123 |
| 2018 | 87 | 48 | 135 |
| 2019 | 67 | 56 | 123 |
| 2020 | 105 | 72 | 177 |
| 2021 | 67 | 101 | 168 |
| 2022 | 14 | 132 | 146 |
| 2023 | 7 | 101 | 108 |
| 2024 | 49 | 73 | 122 |
| 2025 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model. Cancer Discov. 2025 Jan 13; 15(1):162-178.
-
Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy? Neuro Oncol. 2025 Jan 12; 27(1):33-49.
-
OSBPL3 modulates the immunosuppressive microenvironment and predicts therapeutic outcomes in pancreatic cancer. Biol Direct. 2025 Jan 09; 20(1):5.
-
Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing. J Immunother Cancer. 2025 Jan 08; 13(1).
-
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2025 Jan 07; 39(1-2):36-63.
-
Development of a RIPK1 degrader to enhance antitumor immunity. Nat Commun. 2024 Dec 16; 15(1):10683.
-
Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity. J Immunother Cancer. 2024 Dec 09; 12(12).
-
Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer. Nat Commun. 2024 Dec 05; 15(1):10609.
-
Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy. BMC Cancer. 2024 Dec 04; 24(1):1493.
-
Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy. Cells. 2024 Dec 03; 13(23).